Using a disease-affected cell to synthesize its own drug

使用受疾病影响的细胞合成自己的药物

• 批准号: 9149039
• 负责人: Matthew D Disney
• 金额: $ 96万
• 依托单位: SCRIPPS FLORIDA
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-30 至 2020-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9149039
• 关键词: Affect; Animals; Binding; Biology; Biomedical Research; Blood - brain barrier anatomy; Brain; Cells; Chemicals; Code; Custom; Data; Disease; Fragile X Syndrome; Genes; Human; Huntington Disease; Image; Lead; Life; Medicine; Microsatellite Repeats; Modality; Molecular Weight; Muscular Dystrophies; Mutation; Pathology; Patients; Pharmaceutical Preparations; Precision therapeutics; RNA; Reaction; Technology; Therapeutic; Tissues; Toxic effect; Transcript; Untranslated RNA; Weight Gain; catalyst; gene product; genome sequencing; human disease; inhibitor/antagonist; innovation; nervous system disorder; precision medicine

 DESCRIPTION (provided by applicant): One major challenge in biomedical research is to leverage advances in genome sequencing into lead therapeutic modalities to treat human disease. This precision medicine approach holds great promise to advance patient-specific therapeutics and to provide highly selective chemical probes of function to study disease biology. In this proposal, we describe an innovative precision therapeutic approach to custom synthesize highly selective and potent lead therapeutics in only disease-affected cells and tissues by using a disease-causing gene product as a catalyst. That is, the disease-affected cell serves as a reaction vessel and a disease-causing RNA as a catalyst to allow for the synthesis of its own treatment. This is in contrast to traditional precision medicine approaches in which both healthy and disease-affected cells are exposed to the therapeutic, potentially causing toxicity due to binding off-targets. Our technology will be applied to develop compounds to treat and study microsatellite disorders that affect millions of people worldwide and have no known cure. Microsatellite disorders are caused by expanded repeating sequences located in both coding and non-coding regions, with the RNA being a key pathogenic agent. We have previously shown that repeating transcripts are most effectively targeted with multivalent compounds. However, as the compounds increase in valency, their molecular weights increase and their drug- likeness decreases. We therefore recently developed an innovative strategy to synthesize multivalent compounds, from their monovalent components, in cellulo using a disease-affected cell as a reaction vessel and a toxic, disease-causing RNA as a catalyst. We will take these exciting results in new directions and apply them to other debilitating microsatellite disorders including Huntington's disease, various forms of muscular dystrophy, the genetic defect that causes fragile X syndrome (the only known single gene cause of auti

 描述(由申请人提供)：生物医学研究中的一个主要挑战是利用基因组测序的进展来治疗人类疾病。这种精确的医学方法很有希望推进针对患者的治疗方法，并提供高度选择性的功能化学探针来研究疾病生物学。在这项提案中，我们描述了一种创新的精确治疗方法，通过使用致病基因产品作为催化剂，仅在受疾病影响的细胞和组织中定制合成高选择性和有效的铅治疗药物。也就是说，受疾病影响的细胞充当反应容器，而致病RNA充当催化剂，以允许合成自身的治疗方法。这与传统的精确医学方法形成了鲜明对比，在传统的精确医学方法中，健康细胞和受疾病影响的细胞都暴露在治疗性药物中，由于结合靶点外，可能会导致毒性。我们的技术将被应用于开发治疗和研究微卫星疾病的化合物，这些疾病影响着全球数百万人，目前还没有已知的治愈方法。微卫星疾病是由位于编码区和非编码区的扩展重复序列引起的，RNA是关键的致病因子。我们以前已经证明，重复的转录本最有效地靶向多价化合物。然而，随着化合物价态的增加，它们的分子质量增加，它们的类药物性降低。因此，我们最近开发了一种创新的策略，利用受疾病影响的细胞作为反应容器，使用有毒的致病RNA作为催化剂，在纤维素中从单价化合物合成多价化合物。我们将把这些令人兴奋的结果推向新的方向，并将它们应用于其他令人衰弱的微卫星疾病，包括亨廷顿病、各种形式的肌营养不良、导致脆性X综合征的遗传缺陷(唯一已知的导致自闭症的单基因